Edition:
United Kingdom

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

2.47USD
23 May 2018
Change (% chg)

-- (--)
Prev Close
$2.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
90,907
52-wk High
$2.85
52-wk Low
$1.17

Chart for

About

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its... (more)

Overall

Beta: 2.39
Market Cap(Mil.): $153.34
Shares Outstanding(Mil.): 62.39
Dividend: --
Yield (%): --

Financials

  AFMD.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -0.76 -- --
ROI: -56.47 -7.38 12.74
ROE: -60.23 -10.11 14.64

BRIEF-Affimed Announces Proposed Public Offering Of Common Stock

* AFFIMED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

12 Feb 2018

BRIEF-Affimed Reports New Data For AFM13 From Two Separate Clinical Trials

* AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS

01 Feb 2018

BRIEF-Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash

* Affimed presents data from Phase 1B combination study of AFM13 with Pembrolizumab at Ash

11 Dec 2017

Earnings vs. Estimates